255 related articles for article (PubMed ID: 3726361)
21. [Long term efficacy and tolerance of antidiabetic treatments. New data].
Mirouze J
Nouv Presse Med; 1974 Jun; 3(24):1551-4. PubMed ID: 4211493
[No Abstract] [Full Text] [Related]
22. The oral hypoglycaemic agents reassess.
Drug Ther Bull; 1974 Mar; 12(5):17-20. PubMed ID: 4820614
[No Abstract] [Full Text] [Related]
23. [On the use of oral antidiabetic drugs].
Aarseth S
Tidsskr Nor Laegeforen; 1973 Aug; 93(23):1595-601. PubMed ID: 4588815
[No Abstract] [Full Text] [Related]
24. [Biguanides in oral antidiabetic therapy: indications and limitations].
Gregorio F; Filipponi P
Medicina (Firenze); 1988; 8(3):262-8. PubMed ID: 3231038
[No Abstract] [Full Text] [Related]
25. [Indication and method of administration of oral antidiabetic agents].
Tasaka Y
Nihon Rinsho; 1997 Nov; 55 Suppl():99-103. PubMed ID: 9434451
[No Abstract] [Full Text] [Related]
26. Drugs for type 2 diabetes.
Treat Guidel Med Lett; 2008 Jul; 6(71):47-54. PubMed ID: 18583949
[No Abstract] [Full Text] [Related]
27. [Oral therapy of type II diabetes].
Haupt E; Schöffling K
Med Klin (Munich); 1989 Apr; 84(4):203-7. PubMed ID: 2657363
[No Abstract] [Full Text] [Related]
28. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy.
Bell DS
Clin Ther; 2004 Nov; 26(11):1714-27. PubMed ID: 15639686
[TBL] [Abstract][Full Text] [Related]
29. [Sulfonylurea compounds or biguanides in the treatment of type 2 diabetes?].
Mehnert H
Dtsch Med Wochenschr; 1989 Jul; 114(27):1086-8. PubMed ID: 2500320
[No Abstract] [Full Text] [Related]
30. Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment.
Harrigan RA; Nathan MS; Beattie P
Ann Emerg Med; 2001 Jul; 38(1):68-78. PubMed ID: 11423816
[TBL] [Abstract][Full Text] [Related]
31. [Differential therapy using oral antidiabetics].
Mehnert H
Internist (Berl); 1971 Nov; 12(11):468-75. PubMed ID: 4943878
[No Abstract] [Full Text] [Related]
32. Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint.
Fisman EZ; Tenenbaum A; Motro M; Adler Y
Herz; 2004 May; 29(3):290-8. PubMed ID: 15167955
[TBL] [Abstract][Full Text] [Related]
33. Treating type 2 diabetes: targeting the many causative factors.
Sutherland JE; Hoehns JD
J Fam Pract; 2004 May; 53(5):376-88. PubMed ID: 15125823
[No Abstract] [Full Text] [Related]
34. [Oral and dietary treatments of type 2 diabetes].
Godeau T; Charbonnel B
Rev Prat; 1992 May; 42(9):1093-8. PubMed ID: 1496236
[TBL] [Abstract][Full Text] [Related]
35. Rosiglitazone/glimepiride (Avandaryl) for diabetes.
Med Lett Drugs Ther; 2006 Mar; 48(1230):22-4. PubMed ID: 16538189
[No Abstract] [Full Text] [Related]
36. Oral hypoglycemic agents.
Ferner RE
Med Clin North Am; 1988 Nov; 72(6):1323-35. PubMed ID: 3054355
[TBL] [Abstract][Full Text] [Related]
37. [Therapeutic trial of a new antidiabetic with vascular action: 1702 SE].
Jaillard J; Warembourg H
Lille Med; 1972 Oct; 17(9):Suppl 6:1332-6. PubMed ID: 4657429
[No Abstract] [Full Text] [Related]
38. Practical therapeutics--use of oral anti-diabetic agents.
Obel AO
East Afr Med J; 1982 Feb; 59(2):91-5. PubMed ID: 7128503
[No Abstract] [Full Text] [Related]
39. [Answers to questionnaire on antidiabetics].
Goto Y; Kataoka K; Mizuno Y; Tanese T; Yawata M
Nihon Rinsho; 1971 Dec; 29(12):3034-50. PubMed ID: 5169018
[No Abstract] [Full Text] [Related]
40. [Combination therapy of oral hypoglycemic agents which enhance the efficacy of insulin therapy].
Hirose T
Nihon Rinsho; 2012 May; 70 Suppl 3():669-77. PubMed ID: 22768596
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
